Creative Financial Designs Inc. ADV Has $1.84 Million Stake in Amgen Inc. $AMGN

Creative Financial Designs Inc. ADV raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,582 shares of the medical research company’s stock after acquiring an additional 473 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Amgen were worth $1,838,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its holdings in shares of Amgen by 6.9% during the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 11,863 shares of the medical research company’s stock worth $3,312,000 after buying an additional 761 shares in the last quarter. AMG National Trust Bank grew its stake in shares of Amgen by 3.3% during the second quarter. AMG National Trust Bank now owns 9,833 shares of the medical research company’s stock valued at $2,745,000 after purchasing an additional 313 shares during the last quarter. Creekmur Asset Management LLC grew its stake in shares of Amgen by 10.1% during the second quarter. Creekmur Asset Management LLC now owns 2,004 shares of the medical research company’s stock valued at $560,000 after purchasing an additional 184 shares during the last quarter. Kovack Advisors Inc. grew its stake in shares of Amgen by 5.9% during the second quarter. Kovack Advisors Inc. now owns 1,569 shares of the medical research company’s stock valued at $438,000 after purchasing an additional 88 shares during the last quarter. Finally, IFG Advisory LLC grew its stake in shares of Amgen by 0.4% during the second quarter. IFG Advisory LLC now owns 9,183 shares of the medical research company’s stock valued at $2,564,000 after purchasing an additional 40 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research analyst reports. Piper Sandler increased their price target on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Bank of America increased their price target on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 27th. Citigroup increased their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research note on Wednesday, September 24th. Finally, Raymond James Financial began coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $300.94.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

Amgen Price Performance

Shares of AMGN stock opened at $298.43 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The stock has a market cap of $160.66 billion, a PE ratio of 24.40, a PEG ratio of 2.61 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm’s 50 day moving average price is $287.75 and its two-hundred day moving average price is $287.51.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the firm earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.